sPIF

Phase 1Small molecule

CChristopher O'Brien, MD

sPIF is one of 20 small molecule programs targeting Autoimmune Hepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune HepatitisActive, not recruiting

Autoimmune HepatitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Autoimmune Hepatitis

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

2 2

Neoral

Novartis

Approved

—3

Imuran

LLegacy Health System

Approved

3 4

Rayos

RRoxane Laboratories

Approved

2 5

Prograf

VVeloxis Pharmaceuticals

Approved

1 6

Chloroquine Diphosphate

UUniversity of Sao Paulo General Hospital

Approved

2 7

Epidiolex

Jazz Pharmaceuticals

Phase 2

1 8

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 2

1 9

Pulmicort

SSalix

Phase 2

1 10

Orencia

Bristol-Myers Squibb

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autoimmune Hepatitis1 trial

sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS

Completed·—·Phase 1·NCT02239562·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for sPIF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sPIF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sPIF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Christopher O'Brien, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CChristopher O'Brien, MD

sPIF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autoimmune Hepatitis1 trial

References

Drug Info

Quick Facts

Related News